Skip to content
Catalyst

PapersPMID:37822243

The Auxiliary Effects of Low-Molecular-Weight Fucoidan in Locally Advanced Rectal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy Before Surgery: A Double-Blind, Randomized, Placebo-Controlled Study.

Integrative cancer therapies2023The record ↗

  1. Finding, moderate evidenceno difference foundTumour response rate

No finding here moved its endpoint.

What did not

1 findingHow to read these marks →
  • “The ORRs and DCRs did not differ significantly between the fucoidan and placebo groups (P =.973 and P =.543, respectively, Table 1).”
    Study
    RCT
    Participants
    87
    Dose studied
    4 g twice daily orally for 3 months
    Population
    Adults with locally advanced rectal cancer; all patients in both arms received neoadjuvant concurrent chemoradiotherapy with mFOLFOX6 and radiotherapy

Study record

Design
randomised controlled trial
Species
human
Population
Patients with locally advanced rectal cancer (LARC) receiving neoadjuvant concurrent chemoradiotherapy (mFOLFOX6 plus radiotherapy) before surgery; low-molecular-weight fucoidan from Sargassum hemiphyllum versus cellulose placebo
Participants
87
Comparator
placebo
Duration
91 days
Endpoints measured
52